The anti-inflammatory effects of tetracyclines

Cutis

Volumn 75, Issue 4 SUPPL., 2005, Pages 6-11

  Weinberg, Jeffrey M ^a,b,c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c CollaGenex Pharmaceuticals Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CHLORTETRACYCLINE; DEMECLOCYCLINE; DOXYCYCLINE; INSULIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METACYCLINE; METRONIDAZOLE; MINOCYCLINE; NICOTINAMIDE; OXYTETRACYCLINE; PREDNISONE; TETRACYCLINE DERIVATIVE;

ACNE VULGARIS; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL GROWTH; BACTERIAL INFECTION; CHEMICAL COMPOSITION; CICATRICIAL PEMPHIGOID; CLINICAL TRIAL; DEATH; DECUBITUS; DEEP VEIN THROMBOSIS; DEGRADATION; DERMATOLOGY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; EROSIVE GASTRITIS; GASTROINTESTINAL DISEASE; GROWTH INHIBITION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOMODULATION; INSULIN TREATMENT; KIDNEY FAILURE; NAUSEA; NONHUMAN; OSTEOMYELITIS; PEMPHIGOID; PEMPHIGUS VULGARIS; PHOTOSENSITIVITY; PROTEIN EXPRESSION; PYODERMA GANGRENOSUM; REVIEW; RISK ASSESSMENT; RISK FACTOR; ROSACEA; SEPSIS; TOXICITY; VAGINITIS;

ACNE VULGARIS; ANTI-INFLAMMATORY AGENTS; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; HUMANS; SKIN DISEASES, BACTERIAL; TETRACYCLINES;

EID: 18244366080     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Wright AL, Colver GB. Tetracyclines - how safe are they? Clin Exp Dermatol. 1988;13:57-61.
2. Ryan ME, Golub LM. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy. Periodontol 2000. 2000;24:226-238.
3. Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa: Saunders; 2004.
4. Tsankov N, Broshtilova V, Kazandjieva J. Tetracyclines in dermatology. Clin Dermatol. 2003;21:33-39.
5. Cullen S, Crounse R. Cutaneous pharmacology of the tetracyclines. J Invest Dermatol. 1965;45:263-268.
6. Thong YH, Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol. 1979;35:443-446.
7. Calebotta A, Saenz AM, Gonzalez F, et al. Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Int J Dermatol. 1999;38:217-221.
8. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
9. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2:234-245.
10. Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol. 2000;71:521-532.
11. Golub LM, Ciancio S, Ramamurthy NS, et al. Low-dose doxycycline therapy: effect on gingival crevicular fluid collagenase activity in humans. J Periodontal Res. 1990;25:321-330.
12. Alexander MB, Damoulis PD. The role of cytokines in the pathogenesis of periodontal disease. Curr Opin Periodontol 1994:39-53.
13. Golub LM, Ramamurthy N, McNamara T, et al. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med. 1991;2:297-322.
14. Patel R, Attur MG, Dave MN, et al. Regulation of nitric oxide and prostaglandin E2 production by CSAIDS (SB203580) in murine macrophages and bovine chondrocytes stimulated with LPS. Inflamm Res. 1999;48:337-343.
15. Lukkonen A, Sorsa T, Salo T, et al. Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer. 2000;86:577-581.
16. Golub LM, McNamara TF, D'Angelo G, et al. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res. 1987;66:1310-1314.
17. Cunliffe WJ. A Pocket Guide to Acne. London, England: Science Press; 1988:63.
18. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966;78:649-652.
19. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol. 1980;102:443-445.
20. Wilkin JK, DeWitt S. Treatment of rosacea: topical clinciamycin versus oral tetracycline. Int J Dermatol. 1993;32:65-67.
21. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130:753-758.
22. Hornschuh B, Hamm H, Wever S, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol. 1997;36:101-103.
23. Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993;28:998-1000.
24. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol. 1998;23:254-257.
25. Lynch WS, Bergfeld WF. Pyoderma gangrenosum responsive to minocycline hydrochloride. Cutis. 1978;21:535-538.
26. Piamphongsant T. Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol. 1974;91:319-322.
27. Shimizu S, Han-Yaku H. Confluent and reticulated papillomatosis responsive to minocycline. Dermatology. 1997;194:59-61.
28. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464.